Construction at the Norton site is currently underway, with the new offerings anticipated to be operational by late 2027.
With demand for its RNA interference meds booming, Alnylam Pharmaceuticals has commenced work to soup up its flagship ...
With six drugs approved for commercial development, Cambridge-based drugmaker Alnylam Pharmaceuticals Inc. is investing $250 ...
Brown Advisory, an investment management company, released its “Brown Advisory Mid-Cap Growth Strategy” third-quarter 2025 ...
UMBC scientists uncovered how enteroviruses initiate replication by assembling a conserved RNA–protein complex inside host ...
Ten of the twelve former Food and Drug Administration (FDA) commissioners and acting commissioners opposed to the Trump ...
Alnylam Pharmaceuticals is expanding its Norton facility with a $250 million investment to enhance RNAi therapeutic ...
A key step to deliver RNAi therapeutics to diverse cell types and tissues beyond the liver from the collaboration of ...
Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is ...
Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM ...
Bangladesh is once again in the grip of a severe dengue and chikungunya crisis in 2025. Hospitals are overwhelmed, fever ...
After a U.S. Court of Appeals Court decision in October that upheld the U.S. Department of Agriculture’s (USDA) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback